eprintid: 10162443
rev_number: 8
eprint_status: archive
userid: 699
dir: disk0/10/16/24/43
datestamp: 2023-01-05 12:02:00
lastmod: 2024-06-26 15:35:34
status_changed: 2023-01-05 12:02:00
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Maselkar, Sheetal
creators_name: Kiazand, Alexandre
creators_name: Templeton, Alison
creators_name: Montgomery, Hugh
creators_name: Esser, Mark T
title: Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply
ispublished: pub
subjects: WHITT
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G94
keywords: Antibodies, Monoclonal, Humans
note: This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
date: 2023-01
date_type: published
publisher: Elsevier
official_url: https://doi.org/10.1016/S2213-2600(22)00450-7
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1997475
doi: 10.1016/S2213-2600(22)00450-7
medium: Print-Electronic
pii: S2213-2600(22)00450-7
lyricists_name: Montgomery, Hugh
lyricists_id: HEMON01
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: The Lancet Respiratory Medicine
volume: 11
number: 1
pagerange: e7-e8
event_location: England
citation:        Maselkar, Sheetal;    Kiazand, Alexandre;    Templeton, Alison;    Montgomery, Hugh;    Esser, Mark T;      (2023)    Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply.                   The Lancet Respiratory Medicine , 11  (1)   e7-e8.    10.1016/S2213-2600(22)00450-7 <https://doi.org/10.1016/S2213-2600%2822%2900450-7>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10162443/1/main%20%287%29.pdf